The effect of the combination treatment with tiotropium and olodaterol compared to tiotropium on symptoms, respiratory functions and physical activity in maintenance naive Japanese patient with COPD

INTERVENTION: Participants take Spiolto respimat(tiotropim bromide hydrate/olodaterol hydrochloride) or Spiriva respimat(tiotropium bromide hydrate) for 12 weeks. CONDITION: Chronic Obstructive Pulmonary Disease PRIMARY OUTCOME: Forced expiratory volume 1 second at 12 weeks SECONDARY OUTCOME: Physical activity (measured by accelerometer); Quality of life (COPD assessment test); Inspiratory capacity; Symptoms (TDI score); Six minuites walk distance and Borg's scale INCLUSION CRITERIA: 1) Patients who are over 40 years old and under 85 years old 2) male and female 3) COPD (FEV 1 / FVC <70%) diagnosis in respiratory function test after bronchodilator inhalation, and those with% FEV 1 <80% 4) Current smoker (10 pack‐years or more) or smoker (smoking history of 10 pack‐years or more, and quit smoking for over 1 year) 5) In the past 12 months, those who have not received periodic treatment for COPD Treatment for COPD refers to treatment with LABA, LAMA, ICS. ICS, LABA, tulobuterol patches should not be used for the past month. 6) Patients who obtained consent in writing about participation in this research